Thrombin inhibitors based on [5,5] trans-fused indane lactams
M Pass1, S Abu-Rabie, A Baxter
1Glaxo Wellcome Research and Development, Stevenage, Herts, United Kingdom. mp8073@glaxowellcome.co.uk
Bioorganic & Medicinal Chemistry Letters
|July 9, 1999
Summary
Researchers synthesized novel trans-fused lactams with an indane core. Compound 19 demonstrated improved plasma stability and significant in vitro anticoagulant effects, outperforming its lactone analog.
Area of Science:
- Medicinal Chemistry
- Organic Synthesis
- Pharmacology
Background:
- Lactam and lactone structures are common in biologically active molecules.
- Indane derivatives have shown diverse pharmacological properties.
- Developing stable anticoagulant agents remains a significant therapeutic challenge.
Purpose of the Study:
- To synthesize and characterize novel trans-fused lactam compounds incorporating the indane nucleus.
- To evaluate the plasma stability and in vitro anticoagulant activity of these novel lactams.
- To compare the properties of the synthesized lactams with their corresponding lactone analogs.
Main Methods:
- Multi-step organic synthesis to prepare a series of trans-fused lactams.
- Characterization of synthesized compounds using spectroscopic techniques.
- In vitro assays to assess plasma stability and anticoagulant activity (e.g., Prothrombin Time, Activated Partial Thromboplastin Time).
Main Results:
- Successful synthesis of a series of trans-fused lactams containing the indane moiety.
- Compound 19 exhibited significantly enhanced plasma stability compared to its lactone counterpart.
- Compound 19 demonstrated appreciable in vitro anticoagulant activity.
Conclusions:
- Trans-fused lactams based on the indane nucleus represent a promising class of compounds.
- The enhanced plasma stability of Compound 19 suggests potential for improved pharmacokinetic profiles.
- These findings warrant further investigation into the therapeutic potential of these novel lactam derivatives as anticoagulants.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...


